Treatment of Femoropopliteal Disease with a Novel Sirolimus-Eluting BRS: First-In-Human Results of the EFEMORAL I Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; Bard Medical; Boston Scientific Corporation; Medtronic; Philips; W.L. Gore & Associates; Cook Medical; Inari Medical; Concept Medical</li></ul>